The role of thoracic radiotherapy as an adjunct to standard chemotherapy in limited-stage small-cell lung cancer

Current Oncology

Volumn 7, Issue 3, 2000, Pages 162-172

  Okawara, G ^a   Gagliardi, A ^a   Evans, W K ^a   Alam, Y ^a   Campling, B ^a   Darling, G ^a   Feld, R ^a   Findlay, B ^a   Goss, G ^a   Graham, I ^a   Gregg, R ^a   Iscoe, N ^a   Kocha, W ^a   Kolin, A ^a   Kotalik, J ^a   Logan, D ^a   Lopez, P ^a   Malthaner, R ^a   Maziak, D ^a   McIvor, A ^a   Miller, J ^a   Rusthoven, J ^a   Shepherd, F ^a   Stewart, D ^a   Urschel, J ^a   Vincent, M ^a   Wenckebach, G ^a   more..

^a CANCER CARE ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COOPERATION; DOSE RESPONSE; HUMAN; LUNG SMALL CELL CANCER; META ANALYSIS; PRACTICE GUIDELINE; RADIATION DOSE DISTRIBUTION; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0033744808     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Considerations on radiotherapy dose intensity for limited small cell lung cancer
2. Combined modality therapy for small cell lung cancer
3. Effect of thoracic radiotherapy on mortality in limited small cell lung cancer. A meta-analysis of 13 randomized trials among 2,140 patients
4. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
5. A meta-analysis of thoracic radiotherapy for small-cell lung cancer
6. The influence of age on the delivery, tolerance, and efficacy of thoracic irradiation in the combined modality treatment of limited stage small cell lung cancer
7. Combined platinum etoposide with radiation therapy in limited stage small cell lung cancer: An effective treatment strategy
8. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: Preliminary results of the Japan Clinical Oncology Group
9. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. 'Petites Cellules' Group
10. Chemotherapy with or without radiation therapy in limited small-cell carcinoma of the lung
11. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: An update of Cancer and Leukemia Group B Study 8083
12. Thoracic radiation therapy added to chemotherapy in limited small cell lung cancer. An update of Cancer and Leukemia Group B (CALGB) study 8083
13. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group
14. Timing of chest irradiation (CI) with respect to combination chemotherapy in small cell lung cancer (SCLC), limited disease (LD)
15. Randomized study of initial versus late chest irradiation combined with chemotherapy in limited-stage small-cell lung cancer. Aarhus Lung Cancer Group
16. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study
17. The effect of dose of thoracic irradiation on recurrence in patients with limited stage small cell lung cancer. Initial results of a Canadian Multicenter Randomized Trial
18. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide
19. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small-cell lung carcinoma
20. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
21. Multimodal therapy for limited small-cell lung cancer: A randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: A Southwest Oncology Group Study